Industry Research Reports
Home > Reports > Machinery & Equipment > Global Cell therapy Processing Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Cell therapy Processing Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Machinery & Equipment
Published Date: 2025-10-30
Pages: 153 Pages
Report ld: 5302708
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
The global Cell therapy Processing market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
From a downstream perspective, Cardiovascular Disease accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Cell therapy Processing leading manufacturers including Anthrogenesis Corp., BioNTech, Cell Ideas, Epic Sciences, Roche, FuGENE, IBC Pharmaceuticals Inc., Bluebird Bio Inc., Immodulon-Therapeutics, Immunomedics Inc., etc., dominate supply; the top five capture approximately % of global revenue, with Anthrogenesis Corp. leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Cell therapy Processing market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Anthrogenesis Corp.
- BioNTech
- Cell Ideas
- Epic Sciences
- Roche
- FuGENE
- IBC Pharmaceuticals Inc.
- Bluebird Bio Inc.
- Immodulon-Therapeutics
- Immunomedics Inc.
- Juno Therapeutics Inc.
- Medlmmune Inc.
- NeoStem Oncology
- Neurotech USA
- Novartis
- Persimmune Inc.
- Pluristem Therapeutics
- BioMed Valley Discoveries Inc.
- Regeneron Pharmaceuticals Inc.
- UCL Business PLC.
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Products
- Services
- Software
Segment by Application
- Cardiovascular Disease
- Bone Repair
- Neurological Disorders
- Skeletal Muscle RepairImmune Diseases
CHAPTER OUTLINE
Chapter 1: Defines the Cell therapy Processing study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; top-tier players 2024 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Cell therapy Processing: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Cell therapy Processing Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Products
1.2.3 Services
1.2.4 Software
1.3 Market Segmentation by Application
1.3.1 Global Cell therapy Processing Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cardiovascular Disease
1.3.3 Bone Repair
1.3.4 Neurological Disorders
1.3.5 Skeletal Muscle RepairImmune Diseases
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Cell therapy Processing Revenue Estimates and Forecasts 2020-2031
2.2 Global Cell therapy Processing Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Cell therapy Processing Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Cell therapy Processing Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Products Market Size by Players
3.3.2 Services Market Size by Players
3.3.3 Software Market Size by Players
3.4 Global Cell therapy Processing Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Cell therapy Processing Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Cell therapy Processing Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Cell therapy Processing Market Size by Type (2020-2031)
6.4 North America Cell therapy Processing Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Cell therapy Processing Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Cell therapy Processing Market Size by Type (2020-2031)
7.4 Europe Cell therapy Processing Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Cell therapy Processing Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Cell therapy Processing Market Size by Type (2020-2031)
8.4 Asia-Pacific Cell therapy Processing Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Cell therapy Processing Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Cell therapy Processing Market Size by Type (2020-2031)
9.4 Central and South America Cell therapy Processing Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Cell therapy Processing Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Cell therapy Processing Market Size by Type (2020-2031)
10.4 Middle East and Africa Cell therapy Processing Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Cell therapy Processing Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Anthrogenesis Corp.
11.1.1 Anthrogenesis Corp. Corporation Information
11.1.2 Anthrogenesis Corp. Business Overview
11.1.3 Anthrogenesis Corp. Cell therapy Processing Product Features and Attributes
11.1.4 Anthrogenesis Corp. Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.1.5 Anthrogenesis Corp. Cell therapy Processing Revenue by Product in 2024
11.1.6 Anthrogenesis Corp. Cell therapy Processing Revenue by Application in 2024
11.1.7 Anthrogenesis Corp. Cell therapy Processing Revenue by Geographic Area in 2024
11.1.8 Anthrogenesis Corp. Cell therapy Processing SWOT Analysis
11.1.9 Anthrogenesis Corp. Recent Developments
11.2 BioNTech
11.2.1 BioNTech Corporation Information
11.2.2 BioNTech Business Overview
11.2.3 BioNTech Cell therapy Processing Product Features and Attributes
11.2.4 BioNTech Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.2.5 BioNTech Cell therapy Processing Revenue by Product in 2024
11.2.6 BioNTech Cell therapy Processing Revenue by Application in 2024
11.2.7 BioNTech Cell therapy Processing Revenue by Geographic Area in 2024
11.2.8 BioNTech Cell therapy Processing SWOT Analysis
11.2.9 BioNTech Recent Developments
11.3 Cell Ideas
11.3.1 Cell Ideas Corporation Information
11.3.2 Cell Ideas Business Overview
11.3.3 Cell Ideas Cell therapy Processing Product Features and Attributes
11.3.4 Cell Ideas Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.3.5 Cell Ideas Cell therapy Processing Revenue by Product in 2024
11.3.6 Cell Ideas Cell therapy Processing Revenue by Application in 2024
11.3.7 Cell Ideas Cell therapy Processing Revenue by Geographic Area in 2024
11.3.8 Cell Ideas Cell therapy Processing SWOT Analysis
11.3.9 Cell Ideas Recent Developments
11.4 Epic Sciences
11.4.1 Epic Sciences Corporation Information
11.4.2 Epic Sciences Business Overview
11.4.3 Epic Sciences Cell therapy Processing Product Features and Attributes
11.4.4 Epic Sciences Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.4.5 Epic Sciences Cell therapy Processing Revenue by Product in 2024
11.4.6 Epic Sciences Cell therapy Processing Revenue by Application in 2024
11.4.7 Epic Sciences Cell therapy Processing Revenue by Geographic Area in 2024
11.4.8 Epic Sciences Cell therapy Processing SWOT Analysis
11.4.9 Epic Sciences Recent Developments
11.5 Roche
11.5.1 Roche Corporation Information
11.5.2 Roche Business Overview
11.5.3 Roche Cell therapy Processing Product Features and Attributes
11.5.4 Roche Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.5.5 Roche Cell therapy Processing Revenue by Product in 2024
11.5.6 Roche Cell therapy Processing Revenue by Application in 2024
11.5.7 Roche Cell therapy Processing Revenue by Geographic Area in 2024
11.5.8 Roche Cell therapy Processing SWOT Analysis
11.5.9 Roche Recent Developments
11.6 FuGENE
11.6.1 FuGENE Corporation Information
11.6.2 FuGENE Business Overview
11.6.3 FuGENE Cell therapy Processing Product Features and Attributes
11.6.4 FuGENE Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.6.5 FuGENE Recent Developments
11.7 IBC Pharmaceuticals Inc.
11.7.1 IBC Pharmaceuticals Inc. Corporation Information
11.7.2 IBC Pharmaceuticals Inc. Business Overview
11.7.3 IBC Pharmaceuticals Inc. Cell therapy Processing Product Features and Attributes
11.7.4 IBC Pharmaceuticals Inc. Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.7.5 IBC Pharmaceuticals Inc. Recent Developments
11.8 Bluebird Bio Inc.
11.8.1 Bluebird Bio Inc. Corporation Information
11.8.2 Bluebird Bio Inc. Business Overview
11.8.3 Bluebird Bio Inc. Cell therapy Processing Product Features and Attributes
11.8.4 Bluebird Bio Inc. Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.8.5 Bluebird Bio Inc. Recent Developments
11.9 Immodulon-Therapeutics
11.9.1 Immodulon-Therapeutics Corporation Information
11.9.2 Immodulon-Therapeutics Business Overview
11.9.3 Immodulon-Therapeutics Cell therapy Processing Product Features and Attributes
11.9.4 Immodulon-Therapeutics Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.9.5 Immodulon-Therapeutics Recent Developments
11.10 Immunomedics Inc.
11.10.1 Immunomedics Inc. Corporation Information
11.10.2 Immunomedics Inc. Business Overview
11.10.3 Immunomedics Inc. Cell therapy Processing Product Features and Attributes
11.10.4 Immunomedics Inc. Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Juno Therapeutics Inc.
11.11.1 Juno Therapeutics Inc. Corporation Information
11.11.2 Juno Therapeutics Inc. Business Overview
11.11.3 Juno Therapeutics Inc. Cell therapy Processing Product Features and Attributes
11.11.4 Juno Therapeutics Inc. Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.11.5 Juno Therapeutics Inc. Recent Developments
11.12 Medlmmune Inc.
11.12.1 Medlmmune Inc. Corporation Information
11.12.2 Medlmmune Inc. Business Overview
11.12.3 Medlmmune Inc. Cell therapy Processing Product Features and Attributes
11.12.4 Medlmmune Inc. Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.12.5 Medlmmune Inc. Recent Developments
11.13 NeoStem Oncology
11.13.1 NeoStem Oncology Corporation Information
11.13.2 NeoStem Oncology Business Overview
11.13.3 NeoStem Oncology Cell therapy Processing Product Features and Attributes
11.13.4 NeoStem Oncology Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.13.5 NeoStem Oncology Recent Developments
11.14 Neurotech USA
11.14.1 Neurotech USA Corporation Information
11.14.2 Neurotech USA Business Overview
11.14.3 Neurotech USA Cell therapy Processing Product Features and Attributes
11.14.4 Neurotech USA Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.14.5 Neurotech USA Recent Developments
11.15 Novartis
11.15.1 Novartis Corporation Information
11.15.2 Novartis Business Overview
11.15.3 Novartis Cell therapy Processing Product Features and Attributes
11.15.4 Novartis Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.15.5 Novartis Recent Developments
11.16 Persimmune Inc.
11.16.1 Persimmune Inc. Corporation Information
11.16.2 Persimmune Inc. Business Overview
11.16.3 Persimmune Inc. Cell therapy Processing Product Features and Attributes
11.16.4 Persimmune Inc. Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.16.5 Persimmune Inc. Recent Developments
11.17 Pluristem Therapeutics
11.17.1 Pluristem Therapeutics Corporation Information
11.17.2 Pluristem Therapeutics Business Overview
11.17.3 Pluristem Therapeutics Cell therapy Processing Product Features and Attributes
11.17.4 Pluristem Therapeutics Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.17.5 Pluristem Therapeutics Recent Developments
11.18 BioMed Valley Discoveries Inc.
11.18.1 BioMed Valley Discoveries Inc. Corporation Information
11.18.2 BioMed Valley Discoveries Inc. Business Overview
11.18.3 BioMed Valley Discoveries Inc. Cell therapy Processing Product Features and Attributes
11.18.4 BioMed Valley Discoveries Inc. Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.18.5 BioMed Valley Discoveries Inc. Recent Developments
11.19 Regeneron Pharmaceuticals Inc.
11.19.1 Regeneron Pharmaceuticals Inc. Corporation Information
11.19.2 Regeneron Pharmaceuticals Inc. Business Overview
11.19.3 Regeneron Pharmaceuticals Inc. Cell therapy Processing Product Features and Attributes
11.19.4 Regeneron Pharmaceuticals Inc. Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.19.5 Regeneron Pharmaceuticals Inc. Recent Developments
11.20 UCL Business PLC.
11.20.1 UCL Business PLC. Corporation Information
11.20.2 UCL Business PLC. Business Overview
11.20.3 UCL Business PLC. Cell therapy Processing Product Features and Attributes
11.20.4 UCL Business PLC. Cell therapy Processing Revenue and Gross Margin (2020-2025)
11.20.5 UCL Business PLC. Recent Developments
12 Cell therapy ProcessingIndustry Chain Analysis
12.1 Cell therapy Processing Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Cell therapy Processing Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Cell therapy Processing Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Cell therapy Processing Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Cell therapy Processing Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Cell therapy Processing Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Cell therapy Processing Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Cell therapy Processing Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Cell therapy Processing Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Cell therapy Processing Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Cell therapy Processing by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell therapy Processing as of 2024)
Table 11. Global Cell therapy Processing Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Cell therapy Processing Companies Headquarters
Table 13. Global Cell therapy Processing Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Cell therapy Processing Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Cell therapy Processing Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Cell therapy Processing Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Cell therapy Processing Revenue by Application (2026-2031) & (US$ Million)
Table 21. Cell therapy Processing High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Cell therapy Processing Growth Accelerators and Market Barriers
Table 25. North America Cell therapy Processing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Cell therapy Processing Growth Accelerators and Market Barriers
Table 27. Europe Cell therapy Processing Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Cell therapy Processing Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Cell therapy Processing Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Cell therapy Processing Investment Opportunities and Key Challenges
Table 31. Central and South America Cell therapy Processing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Cell therapy Processing Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Cell therapy Processing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Anthrogenesis Corp. Corporation Information
Table 35. Anthrogenesis Corp. Description and Major Businesses
Table 36. Anthrogenesis Corp. Product Features and Attributes
Table 37. Anthrogenesis Corp. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Anthrogenesis Corp. Revenue Proportion by Product in 2024
Table 39. Anthrogenesis Corp. Revenue Proportion by Application in 2024
Table 40. Anthrogenesis Corp. Revenue Proportion by Geographic Area in 2024
Table 41. Anthrogenesis Corp. Cell therapy Processing SWOT Analysis
Table 42. Anthrogenesis Corp. Recent Developments
Table 43. BioNTech Corporation Information
Table 44. BioNTech Description and Major Businesses
Table 45. BioNTech Product Features and Attributes
Table 46. BioNTech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. BioNTech Revenue Proportion by Product in 2024
Table 48. BioNTech Revenue Proportion by Application in 2024
Table 49. BioNTech Revenue Proportion by Geographic Area in 2024
Table 50. BioNTech Cell therapy Processing SWOT Analysis
Table 51. BioNTech Recent Developments
Table 52. Cell Ideas Corporation Information
Table 53. Cell Ideas Description and Major Businesses
Table 54. Cell Ideas Product Features and Attributes
Table 55. Cell Ideas Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Cell Ideas Revenue Proportion by Product in 2024
Table 57. Cell Ideas Revenue Proportion by Application in 2024
Table 58. Cell Ideas Revenue Proportion by Geographic Area in 2024
Table 59. Cell Ideas Cell therapy Processing SWOT Analysis
Table 60. Cell Ideas Recent Developments
Table 61. Epic Sciences Corporation Information
Table 62. Epic Sciences Description and Major Businesses
Table 63. Epic Sciences Product Features and Attributes
Table 64. Epic Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Epic Sciences Revenue Proportion by Product in 2024
Table 66. Epic Sciences Revenue Proportion by Application in 2024
Table 67. Epic Sciences Revenue Proportion by Geographic Area in 2024
Table 68. Epic Sciences Cell therapy Processing SWOT Analysis
Table 69. Epic Sciences Recent Developments
Table 70. Roche Corporation Information
Table 71. Roche Description and Major Businesses
Table 72. Roche Product Features and Attributes
Table 73. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Roche Revenue Proportion by Product in 2024
Table 75. Roche Revenue Proportion by Application in 2024
Table 76. Roche Revenue Proportion by Geographic Area in 2024
Table 77. Roche Cell therapy Processing SWOT Analysis
Table 78. Roche Recent Developments
Table 79. FuGENE Corporation Information
Table 80. FuGENE Description and Major Businesses
Table 81. FuGENE Product Features and Attributes
Table 82. FuGENE Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. FuGENE Recent Developments
Table 84. IBC Pharmaceuticals Inc. Corporation Information
Table 85. IBC Pharmaceuticals Inc. Description and Major Businesses
Table 86. IBC Pharmaceuticals Inc. Product Features and Attributes
Table 87. IBC Pharmaceuticals Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. IBC Pharmaceuticals Inc. Recent Developments
Table 89. Bluebird Bio Inc. Corporation Information
Table 90. Bluebird Bio Inc. Description and Major Businesses
Table 91. Bluebird Bio Inc. Product Features and Attributes
Table 92. Bluebird Bio Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Bluebird Bio Inc. Recent Developments
Table 94. Immodulon-Therapeutics Corporation Information
Table 95. Immodulon-Therapeutics Description and Major Businesses
Table 96. Immodulon-Therapeutics Product Features and Attributes
Table 97. Immodulon-Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Immodulon-Therapeutics Recent Developments
Table 99. Immunomedics Inc. Corporation Information
Table 100. Immunomedics Inc. Description and Major Businesses
Table 101. Immunomedics Inc. Product Features and Attributes
Table 102. Immunomedics Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Immunomedics Inc. Recent Developments
Table 104. Juno Therapeutics Inc. Corporation Information
Table 105. Juno Therapeutics Inc. Description and Major Businesses
Table 106. Juno Therapeutics Inc. Product Features and Attributes
Table 107. Juno Therapeutics Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Juno Therapeutics Inc. Recent Developments
Table 109. Medlmmune Inc. Corporation Information
Table 110. Medlmmune Inc. Description and Major Businesses
Table 111. Medlmmune Inc. Product Features and Attributes
Table 112. Medlmmune Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Medlmmune Inc. Recent Developments
Table 114. NeoStem Oncology Corporation Information
Table 115. NeoStem Oncology Description and Major Businesses
Table 116. NeoStem Oncology Product Features and Attributes
Table 117. NeoStem Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. NeoStem Oncology Recent Developments
Table 119. Neurotech USA Corporation Information
Table 120. Neurotech USA Description and Major Businesses
Table 121. Neurotech USA Product Features and Attributes
Table 122. Neurotech USA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Neurotech USA Recent Developments
Table 124. Novartis Corporation Information
Table 125. Novartis Description and Major Businesses
Table 126. Novartis Product Features and Attributes
Table 127. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Novartis Recent Developments
Table 129. Persimmune Inc. Corporation Information
Table 130. Persimmune Inc. Description and Major Businesses
Table 131. Persimmune Inc. Product Features and Attributes
Table 132. Persimmune Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Persimmune Inc. Recent Developments
Table 134. Pluristem Therapeutics Corporation Information
Table 135. Pluristem Therapeutics Description and Major Businesses
Table 136. Pluristem Therapeutics Product Features and Attributes
Table 137. Pluristem Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Pluristem Therapeutics Recent Developments
Table 139. BioMed Valley Discoveries Inc. Corporation Information
Table 140. BioMed Valley Discoveries Inc. Description and Major Businesses
Table 141. BioMed Valley Discoveries Inc. Product Features and Attributes
Table 142. BioMed Valley Discoveries Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. BioMed Valley Discoveries Inc. Recent Developments
Table 144. Regeneron Pharmaceuticals Inc. Corporation Information
Table 145. Regeneron Pharmaceuticals Inc. Description and Major Businesses
Table 146. Regeneron Pharmaceuticals Inc. Product Features and Attributes
Table 147. Regeneron Pharmaceuticals Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Regeneron Pharmaceuticals Inc. Recent Developments
Table 149. UCL Business PLC. Corporation Information
Table 150. UCL Business PLC. Description and Major Businesses
Table 151. UCL Business PLC. Product Features and Attributes
Table 152. UCL Business PLC. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. UCL Business PLC. Recent Developments
Table 154. Raw Materials Key Suppliers
Table 155. Distributors List
Table 156. Market Trends and Market Evolution
Table 157. Market Drivers and Opportunities
Table 158. Market Challenges, Risks, and Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Cell therapy Processing Product Picture
Figure 2. Global Cell therapy Processing Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Products Product Picture
Figure 4. Services Product Picture
Figure 5. Software Product Picture
Figure 6. Global Cell therapy Processing Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Cardiovascular Disease
Figure 8. Bone Repair
Figure 9. Neurological Disorders
Figure 10. Skeletal Muscle RepairImmune Diseases
Figure 11. Cell therapy Processing Report Years Considered
Figure 12. Global Cell therapy Processing Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 14. Global Cell therapy Processing Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Cell therapy Processing Revenue Market Share by Region (2020-2031)
Figure 16. Global Cell therapy Processing Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Products Revenue Market Share by Player in 2024
Figure 19. Services Revenue Market Share by Player in 2024
Figure 20. Software Revenue Market Share by Player in 2024
Figure 21. Global Cell therapy Processing Revenue Market Share by Type (2020-2031)
Figure 22. Global Cell therapy Processing Revenue Market Share by Application (2020-2031)
Figure 23. North America Cell therapy Processing Revenue YoY (2020-2031) & (US$ Million)
Figure 24. North America Top 5 Players Cell therapy Processing Revenue (US$ Million) in 2024
Figure 25. North America Cell therapy Processing Revenue (US$ Million) by Type (2020 - 2031)
Figure 26. North America Cell therapy Processing Revenue (US$ Million) by Application (2020-2031)
Figure 27. US Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 28. Canada Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 29. Mexico Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 30. Europe Cell therapy Processing Revenue YoY (2020-2031) & (US$ Million)
Figure 31. Europe Top 5 Players Cell therapy Processing Revenue (US$ Million) in 2024
Figure 32. Europe Cell therapy Processing Revenue (US$ Million) by Type (2020-2031)
Figure 33. Europe Cell therapy Processing Revenue (US$ Million) by Application (2020-2031)
Figure 34. Germany Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 35. France Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 36. U.K. Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 37. Italy Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 38. Russia Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Cell therapy Processing Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Top 8 Players Cell therapy Processing Revenue (US$ Million) in 2024
Figure 41. Asia-Pacific Cell therapy Processing Revenue (US$ Million) by Type (2020-2031)
Figure 42. Asia-Pacific Cell therapy Processing Revenue (US$ Million) by Application (2020-2031)
Figure 43. Indonesia Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 44. Japan Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 45. South Korea Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 46. Australia Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 47. India Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 48. Indonesia Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 49. Vietnam Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 50. Malaysia Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 51. Philippines Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 52. Singapore Cell therapy Processing Revenue (2020-2031) & (US$ Million)
Figure 53. Central and South America Cell therapy Processing Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Central and South America Top 5 Players Cell therapy Processing Revenue (US$ Million) in 2024
Figure 55. Central and South America Cell therapy Processing Revenue (US$ Million) by Type (2020-2031)
Figure 56. Central and South America Cell therapy Processing Revenue (US$ Million) by Application (2020-2031)
Figure 57. Brazil Cell therapy Processing Revenue (2020-2025) & (US$ Million)
Figure 58. Argentina Cell therapy Processing Revenue (2020-2025) & (US$ Million)
Figure 59. Middle East and Africa Cell therapy Processing Revenue YoY (2020-2031) & (US$ Million)
Figure 60. Middle East and Africa Top 5 Players Cell therapy Processing Revenue (US$ Million) in 2024
Figure 61. South America Cell therapy Processing Revenue (US$ Million) by Type (2020-2031)
Figure 62. Middle East and Africa Cell therapy Processing Revenue (US$ Million) by Application (2020-2031)
Figure 63. GCC Countries Cell therapy Processing Revenue (2020-2025) & (US$ Million)
Figure 64. Israel Cell therapy Processing Revenue (2020-2025) & (US$ Million)
Figure 65. Egypt Cell therapy Processing Revenue (2020-2025) & (US$ Million)
Figure 66. South Africa Cell therapy Processing Revenue (2020-2025) & (US$ Million)
Figure 67. Cell therapy Processing Industry Chain Mapping
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Cell therapy Processing market?
The top companies in the global Cell therapy Processing market are Anthrogenesis Corp.、BioNTech、Cell Ideas.
Related Reports
Cell therapy Processing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Cell therapy Processing was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-07-15
Pages: 133
USD 3950.00
(Single User License)
Global Cell therapy Processing Market Research Report 2026
The global Cell therapy Processing market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-04-28
Pages: 124
USD 2900.00
(Single User License)
Global Cell therapy Processing Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Cell therapy Processing market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-25
Pages: 104
USD 4250.00
(Single User License)
Cell therapy Processing- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Cell therapy Processing was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-25
Pages: 136
USD 3950.00
(Single User License)
Global Cell therapy Processing Market Research Report 2025
The global market for Cell therapy Processing was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-25
Pages: 94
USD 2900.00
(Single User License)
Global Cell therapy Processing Market Insights, Forecast to 2030
Market Analysis and Insights: Global Cell therapy Processing Market
Published Date: 2024-04-25
Pages: 128
USD 4900.00
(Single User License)
Global Cell therapy Processing Market Research Report 2024
The global Cell therapy Processing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published Date: 2024-01-11
Pages: 101
USD 2900.00
(Single User License)
Cell therapy Processing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Cell therapy Processing was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-07-15
Pages: 133
USD 3950.00 (Single User License)Global Cell therapy Processing Market Research Report 2026
The global Cell therapy Processing market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-04-28
Pages: 124
USD 2900.00 (Single User License)Global Cell therapy Processing Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Cell therapy Processing market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-25
Pages: 104
USD 4250.00 (Single User License)Cell therapy Processing- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Cell therapy Processing was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-25
Pages: 136
USD 3950.00 (Single User License)Global Cell therapy Processing Market Research Report 2025
The global market for Cell therapy Processing was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-25
Pages: 94
USD 2900.00 (Single User License)Global Cell therapy Processing Market Insights, Forecast to 2030
Market Analysis and Insights: Global Cell therapy Processing Market
Published: 2024-04-25
Pages: 128
USD 4900.00 (Single User License)Global Cell therapy Processing Market Research Report 2024
The global Cell therapy Processing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published: 2024-01-11
Pages: 101
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now